Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
In this phase II trial we attempt to improve upon the efficacy of the trastuzumab/vinorelbine
combination by adding weekly docetaxel. When administered on a weekly schedule, docetaxel is
well tolerated with minimal myelosuppression, so that it is likely that fully efficacious
doses of all three drugs can be administered